Study Evaluating the Effect of a Specific Trace Metal Complex Versus Placebo on the Severity of Apnea in Patients With Obstructive Sleep Apnea Syndrome

Apnea, Obstructive Clinical Trial

— OLIGO-SAS  

Official title:

Prospective, Randomized, Double-blind, Parallel-group Study Evaluating the Effect of a Specific Trace Metal Complex Versus Placebo on the Severity of Apnea in Patients With Obstructive Sleep Apnea Syndrome

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05758324
• Other study ID #: 2022-A01340-43
• Status: Not yet recruiting
• Phase: N/A
• Start date: March 1, 2023
• Est. completion date: January 31, 2024

Study information

• Verified date: March 2023
• Source: Laboratoires Pronutri
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Obstructive sleep apnea syndrome (OSA) is defined by the association of clinical symptoms - drowsiness in particular - and sleep breathing disorders, objectified by measuring the apnea-hypopnea index (AHI). Apneas and hypopneas during sleep are responsible for micro-arousals and hypoxemia.

In the short term, these result in daytime sleepiness with reduced alertness, difficulty driving and carrying out tasks (increased risk of road accidents and accidents at work), memory and concentration problems. , mood disorders. These disturbances lead to an impairment of the quality of life.

In the long term, severe OSA (AHI > 30 events/hour) increases all-cause mortality and cardiovascular morbidity.

The reference treatment is nasal ventilation by Continuous Positive Airway Pressure (CPAP). In practice, the observance and effectiveness of CPAP are limited by the sometimes difficult acceptance of cumbersome equipment, involving noise pollution and requiring the wearing of night-time equipment that some patients find difficult to bear.

The alternative treatment is represented by the mandibular advancement orthosis . Lifestyle and dietary measures are always recommended.

To date, no pharmacological treatment has demonstrated its effectiveness in OSA.

Studies have shown that the antioxidant capacity of the blood is reduced in patients with OSA. It would be secondary to the cycles of hypoxia and reoxygenation which cause a modification of the oxidative balance, leading to an increase in free radicals. It has been observed that the serum levels of trace elements and heavy metals are higher during OSA, by deterioration of the balance of these substances due to oxidative stress and inflammation.

Antioxidant therapies have reduced biomarkers of oxidative stress in apneic patients.

A new path of research is opening up with the use of antioxidants and trace elements in OSA.

To scientifically support the hypothesis of the action of these supplements based on trace metals on OSA, PRONUTRI wish to conduct a comparative, randomized, double-blind study versus placebo evaluating the effect of a specific complex of trace metals in the OSA.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 42
• Est. completion date: January 31, 2024
• Est. primary completion date: January 31, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• adult patient with moderate to severe sleep apnea-hypopnea syndrome confirmed by polysomnography dating less than 3 months with an apneas/hypopneas index = 15 events/h

• stable weight (5% variation of the weight at the time of the polysomnography done within 3 months)

Exclusion Criteria:

• patient previously treated for OSA by continuous positive airway pressure or mandibular orthosis

• obesity (body mass index > 30 kg/m2)

• pregnant or post-pregnancy women less than 6 months old or of childbearing age without an effective method of contraception

• respiratory, cardiac, hepatic or renal failure

• active cancer or history of cancer

• alcohol abuse

• antidepressant intake

• use of compression stockings

• intake of product or supplementation enriched with trace metals and/or trace elements and/or mineral salts and/or vitamins.

• taking any type of psychotropic medication

• previous intake of trace elements to treat OSA

Related Conditions & MeSH terms

• Apnea
• Apnea, Obstructive
• Sleep Apnea Syndromes
• Sleep Apnea, Obstructive

Intervention

Dietary Supplement:
• Nutri PNEA
4 sequences of 10 tablets (one intake)
• Placebo
4 sequences of 10 tablets (one intake)

Locations

Country	Name	City	State
France	Laboratoire EFCR - CHU de Grenoble	Grenoble

Sponsors (2)

Lead Sponsor	Collaborator
Laboratoires Pronutri	Clin-Experts

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in the number of apneas/hypopneas		60 days
Secondary	Change in Ventilatory Response	Change in Ventilatory Response assessed by tests of Ventilatory Response to Carbon Dioxide (CO2)	60 days
Secondary	Proportion of patients with a 50% reduction in the apnea-hypopnea index	AHI is used to diagnose obstructive sleep apnea by counting respiratory events. An index greater than 5 per hour defines a ventilatory disorder.; AHI defines severity as well, the index is: Mild, between 5 and 15 per hour Moderate, between 15 and 30 per hour Severe, over than 30 per hour	60 days
Secondary	Proportion of patients with an apnea-hypopnea index < 30/hour	AHI is used to diagnose obstructive sleep apnea by counting respiratory events. An index greater than 5 per hour defines a ventilatory disorder.; AHI defines severity as well, the index is: Mild, between 5 and 15 per hour Moderate, between 15 and 30 per hour Severe, over than 30 per hour	60 days
Secondary	Proportion of patients with an apnea-hypopnea index < 15/hour	AHI is used to diagnose obstructive sleep apnea by counting respiratory events. An index greater than 5 per hour defines a ventilatory disorder.; AHI defines severity as well, the index is: Mild, between 5 and 15 per hour Moderate, between 15 and 30 per hour Severe, over than 30 per hour	60 days
Secondary	Change in sleep quality	Sleep quality will be assessed by the Pittsburgh Sleep Quality Index (PSQI) questionnaire. This will be used to measure sleep quality over the last 60 days.The self-related questions include the assessment of seven different sleep domains : sleep quality, sleep latency , sleep duration , habitual sleep efficiency, sleep disturbances , use of sleeping medications , and daytime dysfunction .The seven components scores are then added to yield a global PSQI score in the range of zero to 21. The higher the score, the worse the sleep quality. A global score greater than five is diagnostic of poor sleep quality.	60 days
Secondary	Change in sleepiness	Sleepiness will be assessed by the Epworth Sleepiness Scale (ESS).It will be used to measure daytime sleepiness .It can determine the chance of falling asleep in 8 different circumstances. ESS score can range from 0 to 24. A global score greater than ten is diagnostic of excessive daytime sleepiness .	60 days